Frazier Financial Advisors LLC Decreases Holdings in Stryker Co. (NYSE:SYK)

Frazier Financial Advisors LLC lowered its position in Stryker Co. (NYSE:SYK) by 73.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 124 shares of the medical technology company’s stock after selling 351 shares during the period. Frazier Financial Advisors LLC’s holdings in Stryker were worth $45,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of SYK. Vanguard Group Inc. lifted its stake in shares of Stryker by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company’s stock worth $11,773,213,000 after purchasing an additional 252,188 shares during the period. State Street Corp raised its position in Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after acquiring an additional 316,404 shares during the period. Geode Capital Management LLC grew its position in shares of Stryker by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company’s stock valued at $2,484,893,000 after acquiring an additional 165,490 shares during the period. Norges Bank purchased a new stake in shares of Stryker in the 4th quarter worth $1,710,744,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Stryker by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company’s stock worth $714,715,000 after purchasing an additional 48,819 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Performance

Shares of Stryker stock opened at $367.87 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock’s fifty day moving average price is $384.47 and its 200-day moving average price is $374.24. The firm has a market cap of $140.37 billion, a P/E ratio of 47.41, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 earnings per share. On average, equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Analyst Ratings Changes

Several research analysts have recently commented on SYK shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research note on Tuesday, March 4th. Citigroup restated a “buy” rating and set a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. Finally, Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.